Algunas variables clínicas y de laboratorio en pacientes adultos con leucemia mieloide crónica tratados con interferón alfa recombinante + citosina arabinósido Some clinical and laboratory variables in adult patients with chronic myeloid leukemia treated with recombinant alpha interferon + cytosine arabinoside

Article Spanish OPEN
Espinosa Martínez, Edgardo; Díaz Durán, Carmen Virginia; Ávila Cabrera, Onel; Hernández Padrón, Carlos; Rodríguez, Luis Ramón; Izquierdo Cano, Lisset; Amor Vigil, Ana María; Lavaut Sánchez, Kalia; Espinosa Estrada, Edgardo; Wade Mateo, Maura; Estrada del Cueto, Marianela;
(2011)
  • Publisher: Editorial Ciencias Médicas
  • Journal: Revista Cubana de Hematología (issn: 0864-0289, eissn: 1561-2996)
  • Publisher copyright policies & self-archiving
  • Subject: Leucemia mieloide crónica | RC581-607 | interferón ? recombinante | cytosine arabinoside | Diseases of the blood and blood-forming organs | Chronic myeloid leukemia | recombinant interferon | citosina arabinósido | RC633-647.5 | Immunologic diseases. Allergy

La leucemia mieloide crónica del adulto es la hemopatía maligna más frecuente dentro de los síndromes mieloproliferativos. En un estudio retrospectivo longitudinal realizado entre enero de 1985 y diciembre de 2009, se evaluaron 46 pacientes en fase crónica atendidos en ... View more
  • References (42)
    42 references, page 1 of 5

    2. Lugo T, Pendergast A, Muller A, Witte O. Tyrosine kinase activity and transformation potency of bcr/abl oncogene products. Science. 1990 Mar 2;247(4946):1079-82. PMID: 2408149.

    3. Karridge I. Treatment of adult leukemias. Austr Prescr [serial on the Internet]. 2006 [cited 2011 May 23];29:76-9. Disponible en: http://www.australianprescriber.com/magazine/29/3/76/9

    4. Goldman JM, Melo JV. Chronic myeloid leukemia advances in biology and new approaches to treatment. N Engl J Med. 2003 Oct 9;349(15):1451-64. PMID: 14534339.

    5. Pavithran K. Treatment of chronic myeloid leukemia. Medicine on line. Intern J Med. Priory.com [serial on the Internet]. 2006 [cited 2011 May 23]. Disponible en: http://www.priory.com/med/leuk.htm

    6. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology. Hematology Am Soc Hemato Educ Program 2003:132-52. PMID: 14633780.

    7. Sokal JE, Cox EB, Baccarani M, Tura S, Gómez GA, Robertson JE, et al. Prognostic discrimination in “good risk” chronic granulocytic leukemia. Blood. 1984 Apr;63(4):789-99. PMID: 6584184.

    8. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Amer J Med. 1990 Jan;88(1):1-8. PMID: 2294759.

    9. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998 Jun;90(11):850-8. PMID: 9625174.

    10. Huges TP, Kaeda J, Brandford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003 Oct9;349(15):1423-32. PMID: 14534335.

    11. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in Imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41. PMID: 16775234.

  • Metrics
Share - Bookmark